Scientist / Engineer I, R&D

Danaher Corporation•Marlborough, MA

2d•$75,000 - $90,000•Onsite

About The Position

Bring more to life. Are you ready to accelerate your potential and make a real difference within life sciences, diagnostics and biotechnology? At Cytiva, one of Danaher’s 15+ operating companies, our work saves lives—and we’re all united by a shared commitment to innovate for tangible impact. You’ll thrive in a culture of belonging where you and your unique viewpoint matter. And by harnessing Danaher’s system of continuous improvement, you help turn ideas into impact – innovating at the speed of life. Working at Cytiva means being at the forefront of providing new solutions to transform human health. Our incredible customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, new medicines, and cell and gene therapies. At Cytiva you will be able to continuously improve yourself and us – working on challenges that truly matter with people that care for each other, our customers, and their patients. Take your next step to an altogether life-changing career. Learn about the Danaher Business System which makes everything possible.

Requirements

Bachelor’s, or Master’s degree in chemical engineering or similar biological or chemical science or engineering field.
Relevant industrial and/or research experience in downstream processing.
Strong understanding of bioprocess separations fundamentals.
Strong communication and interpersonal skills to work in diverse team settings.
Strong organizational skills to work on multiple projects in parallel.
A creative mind eager to solve today’s biggest industry challenges.

Nice To Haves

Filtration experience preferred.
Filtration process development for biologics

Responsibilities

Support a team of bioprocess engineers focused on developing new downstream technologies, or developing innovative approaches to use existing technologies.
Collaborate in cross functional teams to design, execute, and analyze experimental data.
Work will span a broad range of therapeutic modalities including monoclonal antibodies, other recombinant proteins, cell and gene therapy, and nucleic acids.